Objectives: To examine the long-term persistence rate with mirabegron in a real-world clinical setting. Methods: We retrospectively collected the data of patients who were prescribed mirabegron. We investigated the persistence rate and the reason for the discontinuation. The analysis included patient's age, diagnosis, Overactive Bladder Symptom Score, prostatic volume, the prescription by specialists for lower urinary tract dysfunction, drug-na€ ıve patients, replacement of antimuscarinics or add-on therapy to antimuscarinics. Results: A total of 556 patients were included. Among them, 401 patients (72%) had overactive bladder and the other 155 (28%) were categorized as having other storage symptoms. During the observation period, 170 patients (42%) with overactive bladder discontinued mirabegron. The reasons for discontinuation in patients with overactive bladder included unmet expectation of treatment (45 patients, 26%), any adverse events (38 patients, 22%) or symptom improvement (37 patients, 22%). The persistence or discontinuation was not related with age, Overactive Bladder Symptom Score, prostatic volume or the prescription by specialists, while older male patients tended to continue mirabegron. The 3-year persistence rates in female and male overactive bladder patients were 46% and 51%, respectively, and these were better than those in patients with storage symptoms without urgency. In female overactive bladder patients, the persistence rate with mirabegron used as add-on therapy to antimuscarinics was higher than that in the drug-na€ ıve patients on the Kaplan-Meier curve.
Introduction
OAB is chronic dysfunctional status of the bladder and defined as urinary urgency with or without urgency incontinence. 1 Behavioral therapies including bladder training, pelvic floor muscle training and fluid management should be offered to all OAB patients as the first-line treatment. Oral or transdermal medicines, such as antimuscarinics and b3-adrenoceptor agonist, are usually offered as the second-line treatment. OAB is commonly recognized as a chronic condition and long-term treatment is usually necessary. However, previous studies reported a low 1-year persistence rate with antimuscarinics ranging from 17% to 35%. 2 The discontinuation of antimuscarinics could be affected by many factors including unmet expectations of the treatment and adverse events, such as dry mouth or constipation.
Unlike antimuscarinics, which act within the parasympathetic nervous system, the recently introduced b3-adrenoreceptor agonist, mirabegron, targets the sympathetic nervous system and stimulates relaxation of the bladder smooth muscle. Several clinical studies showed that mirabegron had similar effects to antimuscarinics and fewer adverse events. A systematic literature review also showed that mirabegron had similar efficacy to most antimuscarinics and lower incidence of dry mouth, one of the main causes of discontinuation of treatment. 3 In detailed urodynamic studies, mirabegron had no negative effect on the bladder contractility or post-void residual urine. 4, 5 With the emergence of mirabegron, switching therapy from antimuscarinics and combination therapy with antimuscarinics and mirabegron could be treatment options for OAB patients who are not satisfied with antimuscarinics.
Favorable profiles of mirabegron in adverse events and the possible treatment options of mirabegron might contribute to a better long-term persistence rate with mirabegron. Thus, we examined the long-term persistence rate with mirabegron in a real-world clinical setting.
Methods
We retrospectively collected the data of patients at Asahikawa Medical University Hospital, Asahikawa, Japan, who were prescribed mirabegron from September 2011 to September 2016. We investigated the continuation or discontinuation of mirabegron, and the reason for the discontinuation until March 2017. If a patient who had been taking mirabegron changed hospital, the time of changing hospital was defined as the last observation time-point. The analysis included patient's age, diagnosis (OAB or storage symptoms without urgency), OABSS, PV (only in men), prescription by a specialist for LUTD, drug-na€ ıve patients, replacement of antimuscarinics or add-on therapy to antimuscarinics. The diagnosis of OAB was made based on OABSS or the presence of urinary urgency. 6 The OABSS is a validated selfassessment questionnaire, and consists of four questions on OAB symptoms (Q1: daytime frequency, Q2: nighttime frequency, Q3: urgency and Q4: urgency incontinence) created by the Japanese Continence Society. 6 A specialist for LUTD was defined as an active member of the Japanese Continence Society who had experience in LUTD treatment for >7 years.
Patients' sex and age, OABSS, and PV (only in men) were compared between the patients who continued and discontinued mirabegron using the Wilcoxon matched-pairs signedranks test or the v 2 -test. The persistence rate with mirabegron was estimated and compared using the Kaplan-Meier method. We also used Cox proportional hazards regression to examine factors influencing the persistence rate of mirabegron. P < 0.05 were regarded as statistically significant.
Results
A total of 556 patients (female/male: 243/313) were included. There were no differences in age and the observation period between female and male patients. A total of 401 patients (72%) had OAB and the other 155 (28%) were categorized as other storage symptoms, such as urinary frequency without urgency, stress incontinence and interstitial cystitis (Table 1) . During the observation period, 170 (42%) and 93 patients (60%) in each group discontinued mirabegron ( Table 2 ). The main reasons for discontinuation included unmet expectation of treatment, any adverse events or symptom improvement.
These three reasons accounted for 26% (unmet expectation), 22% (adverse events) and 22% (symptom improvement) in patients with OAB who discontinued mirabegron, respectively. The prevalence of patients who discontinued mirabegron because of unmet expectation of treatment was higher in patients with storage symptoms without urgency (49%) than in OAB patients (26%) ( Table 2 ). There were no patients who had any cardiovascular events apparently as a result of mirabegron. The continuation or discontinuation of mirabegron was not related with age, OABSS or PV, whereas older male patients tended to continue mirabegron. Male patients who continued mirabegron were older than those who discontinued (74.2 vs 71.2 years, P = 0.01).
The 1-and 3-year persistence rates in female and male OAB patients were 63% and 46%, and 67% and 51%, respectively, and these were better than those in patients categorized as storage symptoms without urgency (Fig. 1) . In male OAB patients, the persistence rate with mirabegron prescribed by specialists for LUTD tended to be higher than that by non-specialists, but there was no significant difference ( Fig. 2) . In female OAB patients, the persistence rate with mirabegron used as add-on therapy to antimuscarinics was significantly higher (P < 0.05) than that in the drug-na€ ıve patients, but was not significantly different from that in the patients receiving mirabegron as a replacement for antimuscarinics (Fig. 3) . In male OAB patients, there was no significant difference in the persistence rate among the three subgroups of patients (Fig. 3) . The details of antimuscarinics combined with mirabegron are shown in Table 3 . In Cox proportional hazards regression, no influencing factors on the persistence rate were detected.
Discussion
In the present study, the 1-and 3-year persistence rates with mirabegron for OAB patients were 63% and 46% in female patients, and 67% and 51% in male patients, respectively. These data were better than the persistence rate with antimuscarinics in previous reports. 2, 7 Furthermore, in female OAB patients, add-on treatment with mirabegron to antimuscarinics resulted in much better continuation compared with drugna€ ıve patients. Combination therapy with antimuscarinics and mirabegron could be a better treatment option for female patients' satisfaction. Mirabegron was first approved in 2011 for the treatment of OAB in Japan, and is now used worldwide. A placebocontrolled phase 3 study of mirabegron showed the similar incidence of adverse events and the greater efficacy compared with a placebo. 8 The incidence rate of any adverse events of placebo, mirabegron and tolterodine was 24.0%, 24.5% and 34.9%, respectively. The prevalence of constipation in mirabegron (3.4%) and tolterodine (3.5%) was similar, whereas dry mouth developed more frequently in the tolterodine group (2.6% vs 13.3%). Previous clinical trials for antimuscarinics showed a higher incidence rate of dry mouth and constipation 9,10 compared with mirabegron. 8 A recent randomized cross-over study also showed that mirabegron had the same efficacy and a lower rate of dry mouth, blurred vision and constipation compared with an antimuscarinic agent imidafenacin.
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The differences in tolerability with these two types of medication could greatly influence the continuation of medication.
In the present study, the reasons for discontinuation of mirabegron were unmet expectation of treatment (26%), adverse events (22%) or improvement of symptoms (22%) in OAB patients. Benner et al. reported the patient-reported reasons for discontinuation of antimuscarinics. According to their study, among the patients who discontinued antimuscarinics, the reasons were "Didn't work as expected" in 46.2%, "I had sideeffects" in 21.1% or "Bladder symptoms have stopped/bladder problem is cured" in 14.5%. 12 The multicenter clinical study reported by Martan et al. showed that the 1-year persistence rate with mirabegron was 71%, but 40.0% and 16.7% of the study patients discontinued mirabegron because of insufficient treatment efficacy and side-effects, respectively. 13 Taken together, the proportion of the reasons for discontinuation seems to be similar between mirabegron and antimuscarinics.
In the present study, the most frequent reason for discontinuation was unmet expectation of treatment. Of the patients categorized as storage symptoms without urgency, 49% discontinued mirabegron as a result of unmet expectation of treatment, whereas 26% of OAB patients discontinued mirabegron. Mirabegron and antimuscarinics are medication for OAB. There is no clear evidence indicating the efficacy of mirabegron or antimuscarinics for urinary frequency or nocturia without OAB, stress urinary incontinence or interstitial cystitis, although we have no highly recommended medications for these symptoms or diseases. These unfit medications understandably lead to disappointing consequences for patients' expectation.
The persistence rate with mirabegron at 1 year varies widely from 12% to 71% in previous studies. [13] [14] [15] [16] [17] [18] [19] A smallscaled study at a urology clinic reported a low persistence rate with mirabegron (12.2%; n = 76) and solifenacin (20.1%; n = 72). 14 In several large cohort studies using clinical databases (n = 1203-4037), just 19-38% of the patients continued mirabegron. [15] [16] [17] Single or multicenter clinical studies including hundreds of patients showed better persistence rates ranging from 63% to 71%. 13 The continuation or discontinuation of medication is affected by several factors other than the efficacy and adverse events, including prescribing doctors, inadequate patients counseling, insufficient recognition of the condition by patients, cost problems and unwillingness to take long-term treatment. In the studies using clinical databases, not only urologists and urogynecologists, but also general practitioners, might be included as prescribing doctors. [15] [16] [17] Patients should recognize the chronic nature of OAB and the need for long-term treatment, and medical specialists for LUTD should counsel patients adequately to take medicines for a long time.
In the present study, the add-on therapy with mirabegron to antimuscarinics in female OAB patients provided a better persistence rate than that in drug-na€ ıve patients, although the multivariable analysis failed to detect it as a significant factor. Martan et al. also showed that the use of mirabegron as combination therapy with antimuscarinics resulted in better persistence. 13 Other factors associated with better persistence with mirabegron were female patients, older aged patients or polypharmacy according to the previous studies. 15, 16 One reason why combination therapy with mirabegron and antimuscarinic resulted in better persistence might be that the patients receiving combination therapy included a greater number of patients with severe OAB. Furthermore, the greater efficacy of combination therapy with mirabegron and antimuscarinics for OAB patients has already been reported. 20 Small-scaled clinical studies and basic research showed that combination therapy with mirabegron and antimuscarinics was effective for treatment of bladder dysfunction and bladder remodeling in neurogenic bladder. [21] [22] [23] Thus, better efficacy of combination therapy could result in a better persistence rate with mirabegron. In the present study, most patients received solifenacin combined with mirabegron. We require further clinical study to know which antimuscarinics work better with mirabegron.
Limitations of the present study include the retrospective nature of the data collection in a single academic hospital. OAB definition was based on the description in medical records. The use of mirabegron as add-on to or replacement of antimuscarinics was decided at the doctors' discretion. The present study included some patients who were of reproductive age and had severe neurogenic OAB as a result of spinal disorders, including spinal cord injury or spina bifida. Mirabegron should be avoided as far as possible by people of reproductive age according to the package insert. We always informed those patients of that issue and gained their agreement. Despite these limitations, the present study showed a better persistence rate with mirabegron in a real-world clinical setting, and the combination treatment with antimuscarinics in female OAB patients is one of the treatment options yielding the patients' satisfaction.
In conclusion, the present study shows a relatively good long-term persistence rate with mirabegron in OAB patients. Combined treatment with antimuscarinics, especially in female OAB patients, could result in a good persistence rate with mirabegron. 
